| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7097827 | MYLAN SPECIALITY LP | Devices, compositions and methods for the pulmonary delivery of aerosolized medicaments |
Apr, 2016
(8 years ago) | |
| US8349294 | MYLAN SPECIALITY LP | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
May, 2020
(3 years ago) | |
| US7442388 | MYLAN SPECIALITY LP | Phospholipid-based powders for drug delivery |
May, 2020
(3 years ago) | |
| US7368102 | MYLAN SPECIALITY LP | Pulmonary delivery of aminoglycosides |
Dec, 2022
(1 year, 4 months ago) | |
| US9421166 | MYLAN SPECIALITY LP | Pulmonary delivery of aminoglycoside |
Dec, 2022
(1 year, 4 months ago) | |
| US8715623 | MYLAN SPECIALITY LP | Pulmonary delivery of aminoglycoside |
Dec, 2022
(1 year, 4 months ago) | |
| US7516741 | MYLAN SPECIALITY LP | Aerosolization apparatus with feedback mechanism |
Jan, 2024
(3 months ago) | |
| USRE47526 | MYLAN SPECIALITY LP | Aerosolization apparatus with air inlet shield |
Apr, 2024
(16 days ago) | |
| US8069851 | MYLAN SPECIALITY LP | Aeorosolization apparatus with air inlet shield |
Sep, 2024
(4 months from now) | |
| US11484671 | MYLAN SPECIALITY LP | Aerosolization apparatus with capsule puncture alignment guide |
Nov, 2024
(6 months from now) | |
| US8664187 | MYLAN SPECIALITY LP | Methods of treatment of endobronchial infections |
Jun, 2025
(1 year, 1 month from now) | |
| US7559325 | MYLAN SPECIALITY LP | Aerosolization apparatus with air inlet shield |
Oct, 2025
(1 year, 6 months from now) | |
| US8869794 | MYLAN SPECIALITY LP | Aerosolization apparatus with capsule puncturing member |
Sep, 2028
(4 years from now) | |
| US10207066 | MYLAN SPECIALITY LP | Aerosolization apparatus with capsule puncture alignment guide |
Nov, 2030
(6 years from now) | |
Tobi Podhaler is owned by Mylan Speciality Lp.
Tobi Podhaler contains Tobramycin.
Tobi Podhaler has a total of 14 drug patents out of which 8 drug patents have expired.
Expired drug patents of Tobi Podhaler are:
- US7097827
- US8349294
- US7442388
- US7368102
- US9421166
- US8715623
- US7516741
- USRE47526
Tobi Podhaler was authorised for market use on 22 March, 2013.
Tobi Podhaler is available in powder;inhalation dosage forms.
Tobi Podhaler can be used as treatment of cystic fibrosis patients with pseudomonas aeruginosa.
The generics of Tobi Podhaler are possible to be released after 04 November, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 22, 2016 |
Drugs and Companies using TOBRAMYCIN ingredient
Market Authorisation Date: 22 March, 2013
Treatment: Treatment of cystic fibrosis patients with pseudomonas aeruginosa
Dosage: POWDER;INHALATION
TOBI PODHALER family patents
